Create Account | Sign In: Author or Forum

 
 
News  |  Journals  |  Conferences  |  Blogs  |  Articles  |  Forums  |  Twitter    
 

 Headlines:

 

Category: Family Medicine | Gastroenterology | Internal Medicine | Oncology | Pathology | Conference News

Back to Journal Articles

AACR: New Noninvasive Colorectal CA Screen Promising

Last Updated: October 16, 2012.

 

Multi-target stool DNA-based test has sensitivity of 98 percent for detecting colorectal cancer

Share |

Comments: (0)

Tell-a-Friend

 

  Related
 
A multi-target stool DNA-based test consisting of exfoliated DNA markers and fecal hemoglobin has high sensitivity for detecting colorectal cancer, according to a study presented at the American Association for Cancer Research's International Conference on Frontiers in Cancer Prevention Research, held from Oct. 16 to 19 in Anaheim, Calif.

TUESDAY, Oct. 16 (HealthDay News) -- A multi-target stool DNA-based test (sDNA-MT) consisting of exfoliated DNA markers and fecal hemoglobin has high sensitivity for detecting colorectal cancer, according to a study presented at the American Association for Cancer Research's International Conference on Frontiers in Cancer Prevention Research, held from Oct. 16 to 19 in Anaheim, Calif.

Graham P. Lidgard, Ph.D., from Exact Sciences Corporation in Madison, Wis., and colleagues used an optimized automated analytic platform and logistic algorithm to assess the performance of sDNA-MT for colorectal cancer screening. Stool samples were analyzed for 1,003 patients from 36 study sites, including 796 control patients with negative colonoscopies or small polyps and 207 patients with confirmed colorectal cancer or dysplasia.

At a nominal specificity of 90 percent, the researchers found that the sDNA-MT sensitivity was 98 percent for detecting colorectal cancer; 57 percent for precursors of ≥1 cm (advanced adenoma or sessile serrate adenoma); and 86 percent for high-grade dysplasia precursors.

"By analyzing samples with confirmed diagnoses from colonoscopy, we were able to build an analytic algorithm that combines our 11 stool-based biomarkers into a single result," Lidgard said in a statement. "We are encouraged by the results of this study for detecting cancer and cancer precursors, especially the precursor lesions with high-grade dysplasia, an abnormality broadly recognized as being associated with a higher risk for progression to cancer itself."

Several authors disclosed financial ties to Exact Sciences Corporation, which developed the test and sponsored the study.

Press Release
More Information

Copyright © 2012 HealthDay. All rights reserved.


Previous: Lipid Profiles Improved in Past Two Decades in United States Next: Chloride-Restriction Lowers Rates of Kidney Injury in ICU

Reader comments on this article are listed below. Review our comments policy.


Submit your opinion:

Name:

Email:

Location:

URL:

Remember my personal information

Notify me of follow-up comments?

advertisement.gif (61x7 -- 0 bytes)
 

Are you a Doctor, Pharmacist, PA or a Nurse?

Join the Doctors Lounge online medical community

  • Editorial activities: Publish, peer review, edit online articles.

  • Ask a Doctor Teams: Respond to patient questions and discuss challenging presentations with other members.

Doctors Lounge Membership Application

 
     

 advertisement.gif (61x7 -- 0 bytes)

 

 

Useful Sites
MediLexicon
  Tools & Services: Follow DoctorsLounge on Twitter Follow us on Twitter | RSS News | Newsletter | Contact us
Copyright © 2001-2014
Doctors Lounge.
All rights reserved.

Medical Reference:
Diseases | Symptoms
Drugs | Labs | Procedures
Software | Tutorials

Advertising
Links | Humor
Forum Archive
CME | Conferences

Privacy Statement
Terms & Conditions
Editorial Board
About us | Email

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.